Clinical trials · Oregon
Chronic Myeloid Leukemia clinical trials in Oregon
We’re tracking 23 recruiting chronic myeloid leukemia studies with a site in Oregon — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Oregon
- NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Baker City, OregonAges 40–75 - NCT05554406RecruitingPhase 2
New drug therapy for high-risk AML
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
Ontario, OregonAges 18–59 - NCT04093570Enrolling by invitationPhase 2
Extension study for people continuing ASTX727 from a prior trial
This study checks whether continuing ASTX727 for people who already benefited from it in an earlier Taiho study is safe and effective. It may be an option if you stayed on ASTX727 at the end of your parent study and your doctor felt it was helping you.
Portland, OregonAges 18 years+ - NCT03779854RecruitingPhase 2
Preventing graft-versus-host disease in kids after stem cell transplant
This trial tests whether removing certain immune cells (T cells) from the donor transplant can lower the risk of chronic graft-versus-host disease (long-term immune attack after transplant) in children and young adults with blood cancers. If you qualify, it may help improve transplant outcomes while tracking safety and side effects.
Portland, OregonAges 6 months–26 years - NCT03471260RecruitingPhase 1/Phase 2
Ivosidenib and venetoclax for IDH1-mutated leukemia or MDS
This Phase 1/2 study tests whether the medicines ivosidenib and venetoclax (with or without azacitidine) can help people with certain “IDH1-mutated” blood cancers like AML or high-risk MDS. It’s meant for patients whose disease has come back, doesn’t respond, or who can’t safely get standard chemotherapy.
Portland, OregonAges 18 years+ - NCT04256317RecruitingPhase 2/Phase 3
Azacitidine pills with or without venetoclax for certain blood cancers
This study tests whether a pill form of azacitidine (ASTX030) helps people with myelodysplastic syndromes (MDS), CMML, or AML. Some groups may also receive venetoclax; the goal is better blood cancer control for people who aren’t good candidates for intensive chemotherapy.
Salem, OregonAges 18 years+ - NCT05304377RecruitingPhase 1
Early trial drug for chronic-phase CML after prior treatments
This Phase 1 study tests ELVN-001 in people with chronic-phase chronic myeloid leukemia (CML) who have had limited benefit or side effects from other CML medicines. It may help shrink leukemia activity safely and find the best dosing for people who still need treatment options.
Portland, OregonAges 18 years+ - NCT06163430RecruitingPhase 1/Phase 2
Testing a new pill for CML after other treatments
This study tests a new targeted pill called TERN-701 for people with chronic myeloid leukemia (CML) that has not responded well to or caused side effects from other targeted therapies. The goal is to see if it is safe and effective.
Eugene, OregonAges 18 years+ - NCT03874052RecruitingPhase 1
Ruxolitinib plus venetoclax and azacitidine for relapsed AML
This early-phase study tests a combination of ruxolitinib with venetoclax, with or without azacitidine, for adults whose acute myeloid leukemia (AML) has come back or does not respond to treatment. It may help by stopping cancer cells from growing and improving blood counts, with the exact plan guided by the study arm you’re assigned to.
Portland, OregonAges 18 years+ - NCT06859424RecruitingPhase 2
Testing a new GVHD prevention method after donor stem cell transplant
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
Portland, OregonAges 18–66 - NCT06950034RecruitingPhase 1
Testing STX-0712 for advanced CMML or AML
This early-phase study tests a new drug called STX-0712 for people with certain types of blood cancers (CMML or AML) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink or control the cancer.
Portland, OregonAges 18 years+ - NCT06357182RecruitingPhase 1
New drug combo for AML patients who can't have strong chemo
This trial tests a new drug combination (iadademstat plus azacitidine and venetoclax) for people with newly diagnosed AML who cannot have or do not want standard intensive chemotherapy. The goal is to see if adding iadademstat makes the treatment work better.
Portland, OregonAges 18 years+ - NCT04659616RecruitingPhase 1
Pemigatinib after standard chemo for newly diagnosed AML
This Phase 1 trial studies whether adding pemigatinib after standard “7+3” chemotherapy can improve outcomes in certain newly diagnosed acute myeloid leukemia (AML) patients. It aims to find a safe dose and see how well the drug works in a very specific AML genetic group.
Portland, OregonAges 18 years+ - NCT06317649RecruitingPhase 2
Venetoclax and HMA for older adults with FLT3-mutated AML
This trial tests a combination of two drugs (venetoclax and a hypomethylating agent) plus a targeted FLT3 inhibitor for older or frail patients with a specific genetic change in their acute myeloid leukemia. The goal is to see if this treatment is safe and effective without using the strongest chemotherapy.
Newberg, OregonAges 18 years+ - NCT07548983RecruitingPhase 1
Ruxolitinib and azacitidine after stem cell transplant for acute myeloid leukemia
This trial tests whether two drugs—ruxolitinib (a JAK inhibitor) and azacitidine (a low-dose chemotherapy)—can help prevent acute myeloid leukemia from coming back after you receive a stem cell transplant from an unrelated donor. The transplant uses a gentler conditioning approach to reduce side effects while fighting the cancer.
Portland, OregonAges 18 years+ - NCT06672146RecruitingPhase 2
New treatments for AML with an IDH2 mutation
This trial tests new treatments for people with newly diagnosed acute myeloid leukemia (AML) that has a change in the IDH2 gene. It aims to find a better option for those who cannot have standard high-dose chemotherapy.
Portland, OregonAges 18 years+ - NCT04065399RecruitingPhase 1/Phase 2
Testing revumenib for relapsed acute leukemia with certain gene changes
This trial tests revumenib, a targeted medicine, to treat acute leukemia that has come back or hasn’t fully gone away. It may help people whose leukemia has specific gene changes (like KMT2A or NPM1) by trying to better control the cancer.
Portland, OregonAges 4 weeks+ - NCT06504459RecruitingPhase 2
Testing a drug combo for certain types of AML
This trial tests a combination of chemotherapy drugs (venetoclax, cladribine, cytarabine, and azacitidine) for people newly diagnosed with specific types of acute myeloid leukemia (AML) who cannot have or choose not to have standard intensive chemotherapy.
Portland, OregonAges 18 years+ - NCT05554393RecruitingPhase 2
Treating intermediate-risk AML in younger adults
This trial compares three different drug combinations for younger adults (18-59) with intermediate-risk AML. You will be assigned to one of three groups: standard chemotherapy (cytarabine + daunorubicin), that same chemotherapy plus venetoclax, or venetoclax combined with azacitidine.
Ontario, OregonAges 18–59 - NCT06652438RecruitingPhase 3
Revumenib plus standard drugs for NPM1 or KMT2A AML
This trial tests adding a new targeted drug, revumenib, to two standard AML medicines (azacitidine and venetoclax) for adults with a specific gene change (NPM1 mutation or KMT2A rearrangement) who cannot receive strong chemotherapy. The goal is to see if the combination works better.
Portland, OregonAges 18 years+ - NCT07007312RecruitingPhase 3
Ziftomenib plus standard chemo for certain AML patients
This trial tests a new drug, ziftomenib, added to standard chemotherapy for adults with untreated acute myeloid leukemia (AML) who have specific gene changes (NPM1 mutation or KMT2A rearrangement). It aims to see if the combination works better than standard treatment alone.
Eugene, OregonAges 18 years+ - NCT06714591RecruitingPhase 1
Testing BL-M11D1 for advanced AML
This trial tests a new drug called BL-M11D1 for people with a type of leukemia that has come back or not responded to standard treatments. It aims to see if the drug is safe and works against cancer cells that have a protein called CD33.
Eugene, OregonAges 18 years+ - NCT03801434RecruitingPhase 2
Ruxolitinib for people with certain eosinophil overgrowth diseases
This trial studies ruxolitinib to treat illnesses where the body makes too many eosinophils (a type of white blood cell) and symptoms or organ damage happen. It may help shrink disease activity when steroids are not enough, cannot be tolerated, or the illness comes back.
Portland, OregonAges 18 years+
Chronic Myeloid Leukemia trials by city in Oregon
Where these studies are running in Oregon
Institutions with a site for the recruiting chronic myeloid leukemia studies listed above.
- Oregon Health and Science University · 18 studies
- Providence Portland Medical Center · 4 studies
- Providence Saint Vincent Medical Center · 4 studies
- Saint Alphonsus Cancer Care Center-Ontario · 4 studies
- Willamette Valley Cancer Institute and Research Center · 3 studies
- Providence Newberg Medical Center · 2 studies
- Providence Willamette Falls Medical Center · 2 studies
- Bay Area Hospital
What taking part in a chronic myeloid leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Chronic Myeloid Leukemia trials in other states
Common questions
- Are there chronic myeloid leukemia clinical trials in Oregon?
- Yes. We're currently tracking 23 recruiting chronic myeloid leukemia studies with a site in Oregon, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a chronic myeloid leukemia study in Oregon?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Oregon to take part?
- Not necessarily. These studies have a site in Oregon, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a chronic myeloid leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New chronic myeloid leukemia studies open in Oregon regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.